ArriVent BioPharma, Inc. (AVBP)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Between 2026-06-21 and 2026-09-19, public records show 1 signal for ArriVent BioPharma, Inc.. Most notable: 2026-08-12: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-09-19 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing material agreement
- Large insider saleHHLR ADVISORS, LTD. (ten_percent_owner) sold $13.0M of stock
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-10 | HHLR ADVISORS, LTD. | ten percent owner | S | 555,555 | 23.37 | $12,983,320 |
| 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD.; HHLR ADVISORS, LTD. | ten percent owner | S | 555,555 | 23.37 | $12,983,320 |
| 2025-07-11 | LaChapelle Robin | officer | M | 2,050 | 2.28 | $4,674 |
| 2025-07-11 | LaChapelle Robin | officer | M | 6,503 | 2.28 | $14,827 |
| 2025-07-11 | LaChapelle Robin | officer | M | 2,600 | 2.28 | $5,928 |
| 2025-07-11 | LaChapelle Robin | officer | M | 2,050 | 2.28 | $4,674 |
| 2025-07-11 | LaChapelle Robin | officer | M | 2,600 | 2.28 | $5,928 |
| 2025-07-11 | LaChapelle Robin | officer | M | 6,503 | 2.28 | $14,827 |
| 2024-09-19 | LaChapelle Robin | officer | M | 2,471 | 2.28 | $5,634 |
| 2024-09-19 | LaChapelle Robin | officer | M | 12,364 | 3.65 | $45,129 |
| 2024-09-19 | LaChapelle Robin | officer | M | 7,164 | 2.28 | $16,334 |
| 2024-09-19 | LaChapelle Robin | officer | M | 2,700 | 6.24 | $16,848 |
| 2024-09-19 | LaChapelle Robin | officer | M | 2,867 | 2.28 | $6,537 |
| 2024-09-19 | LaChapelle Robin | officer | M | 2,700 | 6.24 | $16,848 |
| 2024-09-19 | LaChapelle Robin | officer | M | 2,867 | 2.28 | $6,537 |
| 2024-09-19 | LaChapelle Robin | officer | M | 7,164 | 2.28 | $16,334 |
| 2024-09-19 | LaChapelle Robin | officer | M | 2,471 | 2.28 | $5,634 |
| 2024-09-19 | LaChapelle Robin | officer | M | 12,364 | 3.65 | $45,129 |
| 2024-01-30 | HILLHOUSE INVESTMENT MANAGEMENT, LTD.; HHLR ADVISORS, LTD. | ten percent owner | C | 3,616,041 | — | — |
| 2024-01-30 | HILLHOUSE INVESTMENT MANAGEMENT, LTD.; HHLR ADVISORS, LTD. | ten percent owner | C | 313,076 | — | — |
| 2024-01-30 | HILLHOUSE INVESTMENT MANAGEMENT, LTD.; HHLR ADVISORS, LTD. | ten percent owner | P | 555,555 | 18 | $9,999,990 |
| 2024-01-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC; OrbiMed Advisors IV Ltd; OrbiMed Asia GP IV, L.P. | director | C | 821,827 | — | — |
| 2024-01-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC; OrbiMed Advisors IV Ltd; OrbiMed Asia GP IV, L.P. | director | C | 821,827 | — | — |
| 2024-01-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC; OrbiMed Advisors IV Ltd; OrbiMed Asia GP IV, L.P. | director | C | 469,615 | — | — |
| 2024-01-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC; OrbiMed Advisors IV Ltd; OrbiMed Asia GP IV, L.P. | director | C | 469,615 | — | — |
| 2024-01-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC; OrbiMed Advisors IV Ltd; OrbiMed Asia GP IV, L.P. | director | P | 222,222 | 18 | $3,999,996 |
| 2024-01-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC; OrbiMed Advisors IV Ltd; OrbiMed Asia GP IV, L.P. | director | P | 222,222 | 18 | $3,999,996 |
| 2024-01-30 | GORDON CARL L | director | C | 821,827 | — | — |
| 2024-01-30 | GORDON CARL L | director | C | 821,827 | — | — |
| 2024-01-30 | GORDON CARL L | director | C | 469,615 | — | — |
| 2024-01-30 | GORDON CARL L | director | C | 469,615 | — | — |
| 2024-01-30 | GORDON CARL L | director | P | 222,222 | 18 | $3,999,996 |
| 2024-01-30 | GORDON CARL L | director | P | 222,222 | 18 | $3,999,996 |
| 2024-01-30 | HEALY JAMES | director | C | 1,252,308 | — | — |
| 2024-01-30 | HEALY JAMES | director | P | 444,444 | 18 | $7,999,992 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.
Recent filings
- 2026-08-12 10-Q
- 2026-08-12 8-K
- 2026-06-22 4
- 2026-06-22 4
- 2026-06-22 4
- 2026-06-22 4
- 2026-06-22 8-K
- 2026-05-11 8-K
- 2026-05-11 424B5
- 2026-05-11 10-Q
- 2026-05-11 8-K
- 2026-05-06 SCHEDULE 13G/A
- 2026-04-28 ARS
- 2026-04-28 DEFA14A
- 2026-04-28 DEF 14A
- 2026-03-17 8-K
- 2026-03-05 S-8
- 2026-03-05 10-K
- 2026-03-05 8-K
- 2026-03-05 SCHEDULE 13G/A